| Indication | Project | Phase | Estimated submission | Estimated launch |
| SPECIALTY PHARMA | ||||
| ADHD—adolescent | DAYTRANA (US) | Registration | 2010 | |
| ADHD | VYVANSE (EU) | 3 | 2011 | 2012 |
| ADHD—for use in combination with other ADHD treatments | INTUNIV (US) | 3 | 2010 | 2011 |
| Ulcerative colitis—maintenance of remission treatment | LIALDA (US) | 3 | 2010 | 2011 |
| Diverticulitis | LIALDA/MEZAVANT | 3 | 2012 | 2013 |
| Chronic Kidney disease | FOSRENOL (US) | Pre-registration | ||
| Prevention and reduction of scarring | JUVISTA (EU) | 3 | 2013–2016 | |
| Adjunctive therapy in depression | VYVANSE | 2 | ||
| Cognitive impairment in depression | VYVANSE | 2 | ||
| Negative symptoms and cognitive impairment in schizophrenia | VYVANSE | 2 | ||
| Arteriovenous grafts in hemodialysis patients | SPD 535 | 1 | 2013–2016 | |
| HUMAN GENETIC THERAPIES | ||||
| Gaucher disease Type 1 | VPRIV (EU) | Registration | H2–2009 | 2010 |
| Fabry disease | REPLAGAL (US) | Registration | 2010 | |
| Hereditary angioedema | FIRAZYR (US) | 3 | 2011 | |
| Hunter syndrome CNS | HGT | 1/2 | 2013–2016 | |
| Metachromatic Leukodystrophy ('MLD') | HGT 1110 | Pre-clinical | 2013–2016 | |
| Sanfilippo A syndrome | HGT 1410 | Pre-clinical | 2013–2016 | |
| Globoid Cell Leukodystrophy ('GLD', Krabbe) | HGT 2610 | Pre-clinical | 2013–2016 | |
| Santaris collaboration | 3 targets | Pre-clinical | 2013–2016 | |
To be as brave as the people we help.
